Merck announces new Phase 3 analyses of weekly oral HIV treatment
Merck announced new Phase 3 analyses of its weekly oral HIV treatment islatravir/lenacapavir.
Related stories
Canada’s TSX Composite Rises 0.9% as Oil Prices Tumble
The S&P/TSX Composite Index was up 0.9% at 35,979.08 points as of 10:25 a.m. ET Monday, with lower oil prices lifting sentiment.
M impact | EQUITY | Nov 02, 2026, 03:50 PM UTC
Oracle Details $20 Billion Plan to Fund AI Buildout
Oracle disclosed details of its previously announced plan to raise $20 billion to fund AI infrastructure expansion. Its stock fell Monday.
M impact | EQUITY | Nov 02, 2026, 03:50 PM UTC
Engineers India Shares Jump 15% to Two-Week High After Q2 Results
Engineers India shares closed Monday up 15% at Rs.290, a two-week high, after upbeat September-quarter results. The stock has gained 44% in 2026.
M impact | EQUITY | Nov 02, 2026, 03:48 PM UTC
World Stocks Rebound as Oil Falls and Strong Data Is Published
Global equities rebounded as oil prices declined and strong economic data was published.
M impact | EQUITY | Nov 02, 2026, 03:47 PM UTC
Carnelian, HDFC AMC and L&T Acquire 2.9% Stake in EAAA India Alternatives
The investors collectively acquired the stake through open-market transactions on EAAA India Alternatives’ first day of trading, November 2.
M impact | EQUITY | Nov 02, 2026, 03:47 PM UTC
Global stocks rise as oil falls and data prove positive
M impact | EQUITY | Nov 02, 2026, 03:47 PM UTC